Hence, the expression of PD-L1 currently lacks sufficient biomarker potential in melanoma to identify eligible candidates for anti-PD-1 therapy and judicious patients who would obtain optimal benefits from either monotherapy or combination immunotherapy [80]. This evidence concerns the gene PDCD1 and melanoma.